Siemens Healthineers invests US $137M in new facility in China

CHINA – Siemens Healthineers has officially broken ground on a new research and development (R&D) and manufacturing facility in Shenzhen, China.

With a total investment exceeding US $137 million (1 billion RMB), the facility is expected to be operational by the end of 2027.

This new development spans 63,000 square meters with a total construction area of 98,000 square meters and will operate alongside the company’s existing Shenzhen base under a “dual-site operation” model, collectively forming the Siemens Healthineers (Shenzhen) Innovation Industrial Park.

Once completed, the new facility will triple the operational scale of Siemens Healthineers’ presence in Shenzhen, significantly enhancing its capabilities in R&D, manufacturing, and talent development.

It will focus on the production of cutting-edge technologies, including angiography systems and components for magnetic resonance (MR) imaging.

A highlight of this effort will be the production of DryCool superconducting magnets, which reduce helium requirements from 1,500 liters to less than one liter and operate in a closed-circuit system without the need for a quench pipe.

In addition to its manufacturing goals, the facility will foster industry-academia collaboration within the Xili Lake International Science and Education City, strengthening local innovation and talent pipelines.

“China has always been a source of growth and innovation for Siemens Healthineers,” said Tao Lin, a member of the board of management.

“This new base underscores our commitment to participating in China’s medical innovation ecosystem and supporting the ‘Healthy China’ strategy while fostering global collaboration.”

Since its establishment in 2002, the Shenzhen base has become one of Siemens Healthineers’ largest R&D and production hubs outside Germany.

To date, the base has produced over 9,000 MR systems, achieving a localization rate exceeding 80%.

Notably, in 2024, the Shenzhen team secured NMPA approval for the domestically produced 7T MR system, the MAGNETOM Terra.X. This investment is part of Siemens Healthineers’ broader global expansion strategy.

In 2024, the company announced a US $314 million (£250 million) investment in North Oxfordshire, U.K., for a 56,000-square-meter facility to design and manufacture superconducting magnets for MR scanners that use significantly less helium.

Additionally, in 2023, the company invested $85 million to expand photon-counting CT detector production in Forchheim, Germany.